4D Molecular Therapeutics logo

Vice President, Clinical Development

4D Molecular Therapeutics
August 07, 2026
Remote friendly (United States)
United States
Clinical Research and Development
General Summary
Reporting to the Chief Medical Officer, the VP, Clinical Development, Ophthalmology provides strategic and operational leadership for global development of ophthalmic genetic medicines.

Responsibilities
- Serve as primary medical monitor for multiple ophthalmology clinical trials; oversee patient safety, data integrity, and protocol adherence.
- Direct and mentor medical monitors; ensure timely delivery of critical trial outputs.
- Provide medical leadership for cross-functional workstreams (pharmacovigilance, biostatistics, clinical operations, regulatory affairs, etc.).
- Lead development planning and submissions (protocols/amendments, ICFs/IBs, INDs, annual reports, CSRs, regulatory response documents; and other regulatory documents as needed).
- Partner with Clinical Operations to ensure trial conduct and deliverable timelines.
- Ensure compliance with SOPs and adhere to ICH/GCP and relevant regulatory guidelines.
- Lead/support internal audits and regulatory inspections.
- Support Advisory Board/BOD materials.
- Lead interactions/collaborations with partners and key external stakeholders.
- Travel ~20%.

Qualifications
- MD.
- Clinical training in Ophthalmology (preferred); retina fellowship (plus); Board Certification (preferred).
- 8+ years biopharma drug development experience.
- Phase 3 ophthalmology experience; retinal disease highly preferred.
- Experience with NDA/BLA/MAA submissions (drug approvals a plus).
- Gene therapy experience (plus).

Skills (required/preferred)
- Strong communication, analytical/problem-solving, and strategic planning skills.
- Track record influencing senior leaders; experience presenting to regulatory authorities (US/EU/APAC).
- Strong knowledge of FDA/EMA/ICH/GCP.
- Team leadership and matrixed environment experience.

Compensation
- Base salary range: $350,000–$430,000.